Ozempic Gastroparesis Settlement: New Jersey Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Assessment

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy of accessible, broad-spectrum health education has empowered individuals to make informed decisions about their well-being. Within this tradition, the focus has naturally expanded to include emerging pharmaceutical therapies and their potential long-term effects on patient populations. As the landscape of chronic disease management evolves, so too does the need to examine the real-world implications of widely prescribed medications. One such area of growing attention involves the class of drugs originally developed for metabolic regulation, which have seen significant uptake in recent years. Among the reported concerns associated with these therapies is the potential for gastrointestinal complications, including delayed gastric emptying—a condition that can profoundly affect quality of life. This transition from general health awareness to specific therapeutic risk assessment is critical. For individuals who have experienced adverse outcomes following exposure to these medications, the question of legal recourse becomes paramount. In jurisdictions such as New Jersey, where pharmaceutical liability claims are carefully adjudicated, affected patients may seek representation to address injuries linked to their treatment. The shift from broad health education to targeted legal inquiry represents a natural progression in the ongoing dialogue between medical science and patient advocacy.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its mechanism involves slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. This section examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and risk considerations for affected patients, including settlement-related factors. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate of solid food emptying from the stomach. The condition can lead to malnutrition, weight loss, and impaired quality of life. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These reactions included nausea, vomiting, and diarrhea, with the majority occurring during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with frequencies below 5% included dyspepsia (3.5% for 0.5 mg, 2.7% for 1 mg), gastroesophageal reflux disease (1.9% for 0.5 mg, 1.5% for 1 mg), and gastritis (0.8% for both doses) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

The Pharmacological Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists inhibit gastric motility and slow gastric emptying, which can become pathological in susceptible individuals. Chronic use may lead to sustained impairment of gastric peristalsis, resulting in gastroparesis. The label for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis as a distinct adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This raises questions about the adequacy of warnings regarding the risk of developing gastroparesis. Patients who experience persistent nausea, vomiting, or abdominal discomfort after initiating Ozempic should be evaluated for gastroparesis, especially if symptoms do not resolve with dose adjustment. Risk considerations for affected patients include the timeline between exposure and documented harm. Gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop after prolonged use. The label notes that the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that early symptoms may be transient. However, some patients may develop chronic gastroparesis that persists after discontinuation. The label also warns of serious hypersensitivity reactions, including anaphylaxis and angioedema, which have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While not directly related to gastroparesis, this indicates that the drug can cause severe adverse events requiring prompt medical attention.

Settlement Considerations for Affected Patients

Settlement-related considerations for patients who develop gastroparesis after using Ozempic involve evaluating whether the manufacturer provided adequate warnings. The current label does not list gastroparesis as a specific adverse reaction, which may be relevant in legal claims. Patients should document the timing of symptom onset relative to Ozempic initiation, any dose changes, and the duration of use. Medical records confirming a diagnosis of gastroparesis through gastric emptying scintigraphy or other objective measures are essential. The frequency of gastrointestinal adverse reactions in clinical trials—affecting up to 36.4% of patients—suggests that the risk is substantial, but the label does not quantify the risk of gastroparesis specifically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in risk communication may form the basis for claims that the warnings were inadequate. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, and its pharmacological effect on gastric emptying can contribute to gastroparesis. The label provides data on common gastrointestinal symptoms but does not explicitly warn about gastroparesis. Patients who experience persistent gastrointestinal symptoms should seek medical evaluation and consider legal consultation if they believe the warnings were insufficient. The timeline of symptom onset and objective diagnostic evidence are critical for both medical management and potential settlement claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to gastrointestinal adverse effects, and in some patients, may contribute to the development of gastroparesis—a condition of delayed gastric emptying without mechanical obstruction. Clinical trials show high rates of gastrointestinal reactions (up to 36.4% with Ozempic vs. 15.3% with placebo) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

The current Ozempic label includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a distinct adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of explicit warning may be relevant for patients considering legal action.

What should I do if I developed gastroparesis after taking Ozempic?

If you experience persistent nausea, vomiting, or abdominal discomfort after starting Ozempic, seek medical evaluation. A diagnosis of gastroparesis typically requires gastric emptying scintigraphy. Document the timing of symptom onset relative to Ozempic use, dose changes, and duration. Consider consulting a New Jersey Ozempic gastroparesis injury lawyer to discuss potential settlement claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.